肌肉因子与慢性肾脏病的研究进展
Research Progress on Myokines and Chronic Kidney Disease
DOI: 10.12677/jcpm.2025.46492, PDF,   
作者: 朱 莹, 张欣洲*:深圳市人民医院(暨南大学第二临床医学院)肾内科,广东 深圳
关键词: 慢性肾脏病肌肉因子骨骼肌代谢Chronic Kidney Disease Myokines Skeletal Muscle Metabolism
摘要: 慢性肾脏病(CKD)已成为全球范围内的重大公共卫生问题,其患病率持续上升。CKD患者往往伴有多种并发症,这极大地影响了他们的生活质量,并增加了死亡风险。近期的科学研究强调了肌肉因子在调节各种生理过程中的关键作用。值得注意的是,一些关键肌细胞因子与肾功能恶化存在潜在关联,这提示需要对其病理生理作用进行更深入的研究。本篇文章以慢性肾脏病为本体对象,旨在探究三种关键的肌肉因子——MSTN、irisin和adropin与慢性肾脏病发病机制之间的相互作用,以及它们与慢性肾脏病进展之间的关联,并探讨了由肌肉因子介导的肌肉–肾脏相互作用的研究进展。
Abstract: Chronic kidney disease (CKD) has become a major public health issue worldwide, with its prevalence continuing to rise. CKD patients often suffer from multiple complications, which significantly affect their quality of life and increase the risk of death. Recent scientific research has emphasized the crucial role of myokines in regulating various physiological processes. It is notable that some key myokines are potentially associated with deterioration of renal function, suggesting the need for more in-depth studies on their pathophysiological effects. This article focuses on chronic kidney disease as the main subject, aiming to explore the interactions between three key myokines—MSTN, irisin, and adropin—and the pathogenesis of chronic kidney disease, as well as their associations with the progression of chronic kidney disease, and discusses the research progress of muscle-kidney interactions mediated by myokines.
文章引用:朱莹, 张欣洲. 肌肉因子与慢性肾脏病的研究进展[J]. 临床个性化医学, 2025, 4(6): 175-183. https://doi.org/10.12677/jcpm.2025.46492

参考文献

[1] Levey, A.S. and Coresh, J. (2012) Chronic Kidney Disease. The Lancet, 379, 165-180. [Google Scholar] [CrossRef] [PubMed]
[2] Perl, J., Karaboyas, A., Morgenstern, H., Sen, A., Rayner, H.C., Vanholder, R.C., et al. (2017) Association between Changes in Quality of Life and Mortality in Hemodialysis Patients: Results from the DOPPS. Nephrology Dialysis Transplantation, 32, 521-527. [Google Scholar] [CrossRef] [PubMed]
[3] Wang, L.M., Xu, X. and Zhang, M. (2023) Prevalence of Chronic Kidney Disease in China Results from the Sixth China Chronic Disease and Risk Factor Surveillance. JAMA Internal Medicine, 183, 298-310.
[4] Zhang, L.X., Wang, F. and Wang, L. (2012) Prevalence of Chronic Kidney Disease in China: A Cross-Sectional Survey. The Lancet, 379, 815-822. [Google Scholar] [CrossRef] [PubMed]
[5] Foreman, K.J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., McGaughey, M., et al. (2018) Forecasting Life Expectancy, Years of Life Lost, and All-Cause and Cause-Specific Mortality for 250 Causes of Death: Reference and Alternative Scenarios for 2016-40 for 195 Countries and Territories. The Lancet, 392, 2052-2090. [Google Scholar] [CrossRef] [PubMed]
[6] Pedersen, B.K., Steensberg, A., Fischer, C., et al. (2003) Searching for the Exercise Factor: Is IL-6 a Candidate? Journal of Muscle Research and Cell Motility, 24, 113-119.
[7] Severinsen, M.C.K. and Pedersen, B.K. (2020) Muscle-Organ Crosstalk: The Emerging Roles of Myokines. Endocrine Reviews, 41, 594-609. [Google Scholar] [CrossRef] [PubMed]
[8] Huh, J.Y. (2018) The Role of Exercise-Induced Myokines in Regulating Metabolism. Archives of Pharmacal Research, 41, 14-29. [Google Scholar] [CrossRef] [PubMed]
[9] Lee, B., Shin, M., Park, Y., Won, S. and Cho, K.S. (2021) Physical Exercise-Induced Myokines in Neurodegenerative Diseases. International Journal of Molecular Sciences, 22, Article 5795. [Google Scholar] [CrossRef] [PubMed]
[10] McPherron, A.C., Lawler, A.M. and Lee, S. (1997) Regulation of Skeletal Muscle Mass in Mice by a New TGF-β Superfamily Member. Nature, 387, 83-90. [Google Scholar] [CrossRef] [PubMed]
[11] Langley, B., Thomas, M., Bishop, A., Sharma, M., Gilmour, S. and Kambadur, R. (2002) Myostatin Inhibits Myoblast Differentiation by Down-Regulating MyoD Expression. Journal of Biological Chemistry, 277, 49831-49840. [Google Scholar] [CrossRef] [PubMed]
[12] McFarlane, C., Plummer, E., Thomas, M., Hennebry, A., Ashby, M., Ling, N., et al. (2006) Myostatin Induces Cachexia by Activating the Ubiquitin Proteolytic System through an NF-κB-Independent, FoxO1-Dependent Mechanism. Journal of Cellular Physiology, 209, 501-514. [Google Scholar] [CrossRef] [PubMed]
[13] Dankbar, B., Fennen, M., Brunert, D., Hayer, S., Frank, S., Wehmeyer, C., et al. (2015) Myostatin Is a Direct Regulator of Osteoclast Differentiation and Its Inhibition Reduces Inflammatory Joint Destruction in Mice. Nature Medicine, 21, 1085-1090. [Google Scholar] [CrossRef] [PubMed]
[14] Wang, D.T., Yang, Y.J., Huang, R.H., et al. (2015) Myostatin Activates the Ubiquitin-Proteasome and Autophagy-Lysosome Systems Contributing to Muscle Wasting in Chronic Kidney Disease. Oxidative Medicine and Cellular Longevity, 2015, 1-18. [Google Scholar] [CrossRef] [PubMed]
[15] Yano, S., Nagai, A., Isomura, M., Yamasaki, M., Kijima, T., Takeda, M., et al. (2015) Relationship between Blood Myostatin Levels and Kidney Function: Shimane Cohre Study. PLOS ONE, 10, e0141035. [Google Scholar] [CrossRef] [PubMed]
[16] Yamada, S., Tsuruya, K., Yoshida, H., Tokumoto, M., Ueki, K., Ooboshi, H., et al. (2016) Factors Associated with the Serum Myostatin Level in Patients Undergoing Peritoneal Dialysis: Potential Effects of Skeletal Muscle Mass and Vitamin D Receptor Activator Use. Calcified Tissue International, 99, 13-22. [Google Scholar] [CrossRef] [PubMed]
[17] Verzola, D., Procopio, V., Sofia, A., Villaggio, B., Tarroni, A., Bonanni, A., et al. (2011) Apoptosis and Myostatin mRNA Are Upregulated in the Skeletal Muscle of Patients with Chronic Kidney Disease. Kidney International, 79, 773-782. [Google Scholar] [CrossRef] [PubMed]
[18] Zhang, L., Rajan, V., Lin, E., Hu, Z., Han, H.Q., Zhou, X., et al. (2011) Pharmacological Inhibition of Myostatin Suppresses Systemic Inflammation and Muscle Atrophy in Mice with Chronic Kidney Disease. The FASEB Journal, 25, 1653-1663. [Google Scholar] [CrossRef] [PubMed]
[19] Dong, J., Dong, Y., Chen, Z., Mitch, W.E. and Zhang, L. (2017) The Pathway to Muscle Fibrosis Depends on Myostatin Stimulating the Differentiation of Fibro/Adipogenic Progenitor Cells in Chronic Kidney Disease. Kidney International, 91, 119-128. [Google Scholar] [CrossRef] [PubMed]
[20] Boström, P., Wu, J., Jedrychowski, M.P., Korde, A., Ye, L., Lo, J.C., et al. (2012) A PGC1-α-Dependent Myokine That Drives Brown-Fat-Like Development of White Fat and Thermogenesis. Nature, 481, 463-468. [Google Scholar] [CrossRef] [PubMed]
[21] Mu, A., Wales, T.E., Zhou, H.X., et al. (2023) Irisin Acts through Its Integrin Receptor in a Two-Step Process Involving Extracellular Hsp90α. Molecular Cell, 83, 1903-1920.e12. [Google Scholar] [CrossRef] [PubMed]
[22] Lee, H.J., Lee, J.O., Kim, N., Kim, J.K., Kim, H.I., Lee, Y.W., et al. (2015) Irisin, a Novel Myokine, Regulates Glucose Uptake in Skeletal Muscle Cells via AMPK. Molecular Endocrinology, 29, 873-881. [Google Scholar] [CrossRef] [PubMed]
[23] Zhang, Q.Y., Yang, X., Peng, M., et al. (2022) Post-Treatment with Irisin Attenuates Acute Kidney Injury in Sepsis Mice through Anti-Ferroptosis via the SIRT1/Nrf2 Pathway. Frontiers in Pharmacology, 13, Article 857067. [Google Scholar] [CrossRef] [PubMed]
[24] Wang, P.W., Pang, Q., Zhou, T., et al. (2022) Irisin Alleviates Vascular Calcification by Inhibiting VSMC Osteoblastic Transformation and Mitochondria Dysfunction via AMPK/Drp1 Signaling Pathway in Chronic Kidney Disease. Atherosclerosis, 346, 36-45. [Google Scholar] [CrossRef] [PubMed]
[25] Ebert, T., Focke, D., Petroff, D., Wurst, U., Richter, J., Bachmann, A., et al. (2014) Serum Levels of the Myokine Irisin in Relation to Metabolic and Renal Function. European Journal of Endocrinology, 170, 501-506. [Google Scholar] [CrossRef] [PubMed]
[26] Yang, S., Xiao, F., Pan, L., Zhang, H., Ma, Z., Liu, S., et al. (2015) Association of Serum Irisin and Body Composition with Chronic Kidney Disease in Obese Chinese Adults: A Cross-Sectional Study. BMC Nephrology, 16, Article No. 16. [Google Scholar] [CrossRef] [PubMed]
[27] Lee, M.J., Lee, S.A., Nam, B.Y., Park, S., Lee, S., Ryu, H.J., et al. (2015) Irisin, a Novel Myokine Is an Independent Predictor for Sarcopenia and Carotid Atherosclerosis in Dialysis Patients. Atherosclerosis, 242, 476-482. [Google Scholar] [CrossRef] [PubMed]
[28] He, W.Y., Wu, F., Pang, X.X., et al. (2016) Irisin Is Associated with Urotensin II and Protein Energy Wasting in Hemodialysis Patients. Kidney and Blood Pressure Research, 41, 78-85. [Google Scholar] [CrossRef] [PubMed]
[29] Zhang, S., Chen, Q., Lin, X., Chen, M. and Liu, Q. (2020) A Review of Adropin as the Medium of Dialogue between Energy Regulation and Immune Regulation. Oxidative Medicine and Cellular Longevity, 2020, 1-7. [Google Scholar] [CrossRef] [PubMed]
[30] Grzegorzewska, A.E., Niepolski, L., Mostowska, A., Warchoł, W. and Jagodziński, P.P. (2016) Involvement of Adropin and Adropin-Associated Genes in Metabolic Abnormalities of Hemodialysis Patients. Life Sciences, 160, 41-46. [Google Scholar] [CrossRef] [PubMed]
[31] Hu, W. and Chen, L. (2016) Association of Serum Adropin Concentrations with Diabetic Nephropathy. Mediators of Inflammation, 2016, 1-5. [Google Scholar] [CrossRef] [PubMed]
[32] Memi, G. and Yazgan, B. (2021) Adropin and Spexin Hormones Regulate the Systemic Inflammation in Adenine-Induced Chronic Kidney Failure in Rat. Chinese Journal of Physiology, 64, 194-201. [Google Scholar] [CrossRef] [PubMed]
[33] Yazgan, B., Avcı, F., Memi, G. and Tastekin, E. (2021) Inflammatory Response and Matrix Metalloproteinases in Chronic Kidney Failure: Modulation by Adropin and Spexin. Experimental Biology and Medicine, 246, 1917-1927. [Google Scholar] [CrossRef] [PubMed]
[34] Kaur, R., Krishan, P., Kumari, P., Singh, T., Singh, V., Singh, R., et al. (2023) Clinical Significance of Adropin and Afamin in Evaluating Renal Function and Cardiovascular Health in the Presence of CKD-MBD Biomarkers in Chronic Kidney Disease. Diagnostics, 13, Article 3158. [Google Scholar] [CrossRef] [PubMed]
[35] Boric-Skaro, D., Mizdrak, M., Luketin, M., Martinovic, D., Tokic, D., Vilovic, M., et al. (2021) Serum Adropin Levels in Patients on Hemodialysis. Life, 11, Article 337. [Google Scholar] [CrossRef] [PubMed]
[36] Kałużna, M., Hoppe, K., Schwermer, K., Ibrahim, A.Y., Pawlaczyk, K. and Ziemnicka, K. (2016) Adropin and Irisin Levels in Relation to Nutrition, Body Composition, and Insulin Resistance in Patients with End-Stage Renal Disease on Chronic Hemodialysis and Peritoneal Dialysis. Polish Archives of Internal Medicine, 126, 474-482. [Google Scholar] [CrossRef] [PubMed]
[37] Jasaszwili, M., Billert, M., Strowski, M.Z., Nowak, K.W. and Skrzypski, M. (2020) Adropin as a Fat-Burning Hormone with Multiple Functions—Review of a Decade of Research. Molecules, 25, Article 549. [Google Scholar] [CrossRef] [PubMed]
[38] Luo, F., Li, Q.C., Zhang, F.J., et al. (2020) Protective Effect of Adropin against High Fat Diet-Induced Obese Diabetic Wistar Rats via Nuclear Factor Erythroid 2-Related Factor 2 Pathway. Pharmacognosy Magazine, 16, 250-257.
[39] Mushala, B.A.S. and Scott, I. (2021) Adropin: A Hepatokine Modulator of Vascular Function and Cardiac Fuel Metabolism. American Journal of Physiology-Heart and Circulatory Physiology, 320, H238-H244. [Google Scholar] [CrossRef] [PubMed]
[40] Pourteymour, S., Eckardt, K., Holen, T., Langleite, T., Lee, S., Jensen, J., et al. (2017) Global mRNA Sequencing of Human Skeletal Muscle: Search for Novel Exercise-Regulated Myokines. Molecular Metabolism, 6, 352-365. [Google Scholar] [CrossRef] [PubMed]
[41] Roux, K.J., Kim, D.I., Burke, B. and May, D.G. (2018) BioID: A Screen for Protein-Protein Interactions. Current Protocols in Protein Science, 91. [Google Scholar] [CrossRef] [PubMed]
[42] Fassbinder, T.R.C., Winkelmann, E.R., Schneider, J., Wendland, J. and Oliveira, O.B.D. (2015) Functional Capacity and Quality of Life in Patients with Chronic Kidney Disease in Pre-Dialytic Treatment and on Hemodialysis—A Cross Sectional Study. Jornal Brasileiro de Nefrologia, 37, 47-54. [Google Scholar] [CrossRef] [PubMed]
[43] Cheung, A.K., Chang, T.I., Cushman, W.C., Furth, S.L., Hou, F.F., Ix, J.H., et al. (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International, 99, S1-S87. [Google Scholar] [CrossRef] [PubMed]
[44] Baker, L.A., March, D.S., Wilkinson, T.J., Billany, R.E., Bishop, N.C., Castle, E.M., et al. (2022) Clinical Practice Guideline Exercise and Lifestyle in Chronic Kidney Disease. BMC Nephrology, 23, Article No. 75. [Google Scholar] [CrossRef] [PubMed]
[45] Quiroga, B. and Díez, J. (2025) The Kidney-Skeletal Muscle-Heart Axis in Chronic Kidney Disease: Implications for Myokines. Nephrology Dialysis Transplantation, 40, 255-263. [Google Scholar] [CrossRef] [PubMed]